The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Honoraria - Novartis
Consulting or Advisory Role - Lilly; Merck
Research Funding - AstraZeneca
 
Consulting or Advisory Role - Astellas Pharma; Ipsen; Janssen
Travel, Accommodations, Expenses - Astellas Pharma; Bristol-Myers Squibb; Ipsen
Outcomes in patients (pts) who had received sorafenib (S) as the only prior systemic therapy in the phase 3 CELESTIAL trial of cabozantinib (C) versus placebo (P) in advanced hepatocellular carcinoma (HCC).
 
Robin Kate Kelley
Consulting or Advisory Role - Agios (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Debiopharm Group (Inst)
Research Funding - Adaptimmune (Inst); Agios (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Exelixis (Inst); Lilly (Inst); MedImmune (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst); Regeneron (Inst); Sanofi (Inst); Taiho Pharmaceutical (Inst); Target Pharmasolutions (Inst); Tekmira (Inst)
 
Baek-Yeol Ryoo
No Relationships to Disclose
 
Philippe Merle
No Relationships to Disclose
 
Joong-Won Park
Honoraria - Bayer; Bristol-Myers Squibb
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb; Eisai; Exelixis; Merck; Ono Pharmaceutical
 
Luigi Bolondi
Honoraria - Bayer; Bracco Diagnostics; Bristol-Myers Squibb; Guerbet; Lilly; Meda Pharmaceuticals; Sirtex Medical
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Guerbet; Sirtex Medical
Speakers' Bureau - Bayer; Bracco Diagnostics; Bristol-Myers Squibb; Guerbet; Lilly; Meda Pharmaceuticals; Sirtex Medical
Research Funding - ArQule; Bayer; Bristol-Myers Squibb; Daiichi Sankyo
Travel, Accommodations, Expenses - Bayer; Bracco Diagnostics; Guerbet; Lilly
 
Stephen Lam Chan
Honoraria - Bayer
Consulting or Advisory Role - AstraZeneca/MedImmune; MSD Oncology; Novartis
Speakers' Bureau - Amgen; Bayer; Eisai
Research Funding - Novartis; Sirtex Medical
 
Ho Yeong Lim
No Relationships to Disclose
 
Ari David Baron
Speakers' Bureau - Amgen; Bristol-Myers Squibb; Genentech/Roche; Lilly; Merck
 
Francis Parnis
No Relationships to Disclose
 
Jennifer Knox
No Relationships to Disclose
 
Stéphane Cattan
No Relationships to Disclose
 
Thomas Cheung Yau
Honoraria - Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb
Consulting or Advisory Role - Bristol-Myers Squibb
 
Julie Lougheed
Employment - Exelixis
Stock and Other Ownership Interests - Exelixis
 
Steven Milwee
Employment - Exelixis
Stock and Other Ownership Interests - Amgen; Exelixis; FibroGen
Travel, Accommodations, Expenses - Exelixis
 
Anthony El-Khoueiry
Honoraria - AstraZeneca; Bayer; Bristol-Myers Squibb; Genentech; GlaxoSmithKline
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Genentech/Roche
Speakers' Bureau - Merrimack
Research Funding - Astex Pharmaceuticals
Travel, Accommodations, Expenses - AstraZeneca; Bayer; Bristol-Myers Squibb; Genentech; GlaxoSmithKline
 
Ann-Lii Cheng
Consulting or Advisory Role - Bayer Schering Pharma; Bristol-Myers Squibb; Eisai; Merck Serono; Novartis; Ono Pharmaceutical; ONXEO
Speakers' Bureau - Novartis
Research Funding - Sanofi
 
Tim Meyer
Consulting or Advisory Role - Boehringer Ingelheim; Bristol-Myers Squibb; Novartis
Research Funding - Bayer (Inst); BTG (Inst); Ipsen (Inst)
 
Ghassan K. Abou-Alfa
Consulting or Advisory Role - Agios; Amgen; Antengene; Aptus Clinical; ASLAN Pharmaceuticals; Astellas Pharma; AstraZeneca; Bayer; Boston Scientific; Bristol-Myers Squibb (I); CARsgen Therapeutics; CASI Pharmaceuticals; Celgene; Celgene (I); Celsion; CytomX Therapeutics (I); Daiichi Sankyo; Debiopharm Group; Delcath Systems; Eisai; EMD Serono (I); Exelixis; Gilead Sciences (I); Halozyme; Halozyme (I); Inovio Pharmaceuticals; Ipsen; Medimmune; Merck Serono; Onxeo; PCI Biotech; Roche; Sanofi (I); SERVIER; Silenseed (I); Sillajen; Sirtex Medical; Sirtex Medical; Vicus Therapeutics (I); Yakult Pharmaceutical
Research Funding - Agios (Inst); Array BioPharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); CASI Pharmaceuticals (Inst); Celgene (Inst); Exelixis (Inst); Genentech (Inst); Incyte (Inst); Lilly (Inst); MabVax (Inst); MedImmune (Inst); Momenta Pharmaceuticals (Inst); Novartis (Inst); OncoMed (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Polaris